A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel
Isabell Bernlochner(TUM Klinikum), Dirk Sibbing(Ludwig-Maximilians-Universität München), Brian Baker, Patricia Brown(Eli Lilly (United States)), Chunmei Zhou(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), Albert Schömig(Institut für Umwelttechnologien und Strahlenschutz (Germany)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Adnan Kastrati(Deutsches Herzzentrum München), Tanja Morath(TUM Klinikum), Neehar Gupta(Eli Lilly (United States))
Cited by 10
Related Papers
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Association analyses based on false discovery rate implicate new loci for coronary artery disease
|Nature Genetics|2017|800